Company Analysis

Nkarta, Inc. (NKTX)

Nasdaq: NKTX · Pharmaceutical Preparations · South San Francisco, CA · filing with the SEC since 2019
Grade4.5
◀ Past 4.1● Present 6.3▶ Future 3.2
4 est.

Who runs Nkarta, Inc.

Officers and directors as they report to the SEC on Forms 3, 4 and 5, named as filed
Chief executive, as filed
Hastings Paul J
Chief Executive Officer. First filing Jul 2020, latest Jun 22, 2026, 13 filings in all.
Officers reporting now
3
of 15 people with a filing in the last fifteen months
Directors reporting now
12
26 people on the record since 2020
Officerssales are open-market, Sep 30, 2025 to Sep 30, 2026
NameTitle as filedFirst filingLatest filingSales, 12 months
Hastings Paul JChief Executive OfficerJul 2020Jun 22, 20262 · $100,000
Mahmood NadirPresidentJul 2020Jan 20, 20261 · $0.00
Rose Shawn MarshallChief Medical Officer, Head of Research & DevelopmentJun 2025Jan 8, 2026none
Directorssales are open-market, Sep 30, 2025 to Sep 30, 2026
NameRoleFirst filingLatest filingSales, 12 months
Behbahani AlidirectorJul 2020Jun 11, 2026none
Dybbs MichaeldirectorJul 2020Jun 11, 2026none
George SimeondirectorJul 2020Jun 11, 2026none
Kolchinsky PeterdirectorJul 2020Jun 11, 2026none
Patterson Leone DdirectorJul 2020Jun 11, 2026none
Ra Capital Healthcare Fund LPdirectorApr 2021Jun 11, 2026none
Ra Capital Management, L.P.directorJul 2020Jun 11, 2026none
Ra Capital Nexus Fund, L.P.directorApr 2022Jun 11, 2026none
Scheiner ZacharydirectorJul 2020Jun 11, 2026none
Shah Rajeev M.directorJul 2020Jun 11, 2026none
Thedinga AngeladirectorMar 2022Jun 11, 2026none
Vratsanos GeorgedirectorJun 2024Jun 11, 2026none
Earlier names on the record27, newest filing first

A person is listed as reporting now after a filing in the last fifteen months. The record shows when someone last filed; it does not say why they stopped. Each name links to the filings on sec.gov.

SI Assistanton NKTX · research, not advice